Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia

After allogeneic hematopoietic stem‐cell transplantation (alloHSCT), the chimerism assay is used to monitor cell engraftment and quantify the respective proportions of donor/recipient cells in blood or bone‐marrow samples. Here, we aimed to better assess the utility of determining CD3+ cell chimeris...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HLA 2022-07, Vol.100 (1), p.18-23
Hauptverfasser:	Bendjelloul, Mehdi, Usureau, Cédric, Etancelin, Pascaline, Saidak, Zuzana, Lebon, Delphine, Garçon, Loïc, Marolleau, Jean‐Pierre, Desoutter, Judith, Guillaume, Nicolas
Format:	Artikel
Sprache:	eng
Schlagworte:	acute myeloid leukemia Alleles Chimerism Hematopoietic Stem Cell Transplantation Human health and pathology Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Life Sciences Original prognosis Recurrence Transplantation, Homologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	After allogeneic hematopoietic stem‐cell transplantation (alloHSCT), the chimerism assay is used to monitor cell engraftment and quantify the respective proportions of donor/recipient cells in blood or bone‐marrow samples. Here, we aimed to better assess the utility of determining CD3+ cell chimerism within the first 6 months post alloHSCT. One hundred and thirty five patients diagnosed with acute myeloid leukemia were enrolled in this study. We observed significantly lower overall survival and relapse free survival for patients without full donor chimerism (
ISSN:	2059-2302 2059-2310
DOI:	10.1111/tan.14557